•  

    SMART.
    FOCUSED.
    PROFESSIONAL.
SMART.
FOCUSED.
PROFESSIONAL.

 

OUR MISSION

Developing innovative compounds that
stimulate therapeutic cell-signaling processes
for the treatment of neurodegenerative diseases.

Immunity Pharma’s initial focus is ALS (Lou Gehrig's disease).

 

OUR MISSION

Developing innovative compounds that
stimulate therapeutic cell-signaling processes
for the treatment of neurodegenerative diseases.

Immunity Pharma’s initial focus is ALS (Lou Gehrig's disease).

OUR LATEST NEWS

Immunity Pharma Announces Positive Top Line Results from Phase 2a Trial with IPL344 in ALS Patients

Jerusalem, Israel, January 16, 2024

  • Treatment with IPL344 was well tolerated
  • Changes in the slope of decline in ALSFRS-R demonstrated 48% slower disease progression (p=0.028); and 64% slower progression when adjusted for disease stage and rate (p=0.034)
  • Study suggests benefits in weight gain, respiration, and survival
  • Plasma neurofilament (NfL) reduction observed following IPL344 treatment

Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, today announced

...
Read More

Neurofilament (NfL) Reduction Following IPL344 Treatment of ALS Patients

Jerusalem, Israel, December 10, 2023

  • Indication of neurodegeneration slow down following IPL344 treatment

Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, today updated on biomarker data from its Phase 2a study with IPL344 in ALS. In a poster presented at the 34th international symposium on ALS and motor neuron disease (MND), December 6-8, 2023, in Basel, Switzerland, the company reported an observed numerical reduction in plasma neurofilament NfL concentrations following IPL344

...
Read More